Fresenius Medical Care Sees U.S. Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
We are actively monitoring the novel coronavirus (COVID-19) pandemic. Learn About the steps that we are taking to protect our patients, employees, physicians, and partners. If you are a patient with questions or concerns, please find additional information at FreseniusKidneyCare.com and AzuraVascularCare.com
Success! The link has been copied to your clipboard.
Waltham, Mass. Nov. 3, 2017 – Fresenius Medical Care Renal Therapies Group announced today that four abstracts on Velphoro® (sucroferric oxyhydroxide) have been accepted for presentation at the American Society of Nephrology (ASN) annual Kidney Week held Oct. 31-Nov. 5, 2017 in New Orleans.
The abstracts describe the real world outcomes in serum phosphorus control and a significant reduction in pill burden achieved in hemodialysis patients who switched to Velphoro as part of their routine clinical care.
Two abstracts focus on a two-year follow-up of patients and include sub-analyses based on the patients’ previous phosphate binder therapy. One abstract documents the changes in mineral bone disease markers in hyperphosphatemic patients who achieved target phosphorus ranges. The fourth abstract describes the change in nutritional markers among patients with low serum albumin who switched to Velphoro.
“Real world data demonstrates switching patients to Velphoro doubled the percentage of patients achieving serum phosphorus control. DOPPS Practice Monitor highlights up to 35 percent of patients are outside of their target phosphorus goal at any given time,” explained Mark Costanzo, president, Fresenius Medical Care Renal Therapies Group.
All four abstracts were accepted for poster presentations on Thursday, Nov. 2. All four are available online on the conference’s website: https://www.asn-online.org/education/kidneyweek/2017/program-search-abstract.aspx.
Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.
For more information, please see full Prescribing Information, contact your Fresenius Medical Care North America representative or visit www.Velphoro.us/hcp.
Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world’s largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.